Recent News

• 05.30.2026 - Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
• 05.30.2026 - Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs
• 05.22.2026 - BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung
• 05.22.2026 - BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
• 05.15.2026 - BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
• 05.15.2026 - Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu
• 05.07.2026 - BioNTech Announces New ADS Repurchase Program
• 05.07.2026 - BioNTech kündigt neues Rückkaufprogramm für American Depositary Shares an

Recent Filings

• 05.22.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.22.2026 - EX-99.1 EX-99.1
• 05.15.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.15.2026 - EX-99.1 EX-99.1
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.13.2026 - 4 Statement of changes in beneficial ownership of securities